non-small cell lung cancer and triple-negative breast cancer. Additional trials will explore combining BNT327/PM8002 and BioNTech’s proprietary antibody-drug conjugates (“ADCs”). In June 2024, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback